KR20240146015A - 방사성 핵종 복합체의 대규모 합성 방법 - Google Patents
방사성 핵종 복합체의 대규모 합성 방법 Download PDFInfo
- Publication number
- KR20240146015A KR20240146015A KR1020247028693A KR20247028693A KR20240146015A KR 20240146015 A KR20240146015 A KR 20240146015A KR 1020247028693 A KR1020247028693 A KR 1020247028693A KR 20247028693 A KR20247028693 A KR 20247028693A KR 20240146015 A KR20240146015 A KR 20240146015A
- Authority
- KR
- South Korea
- Prior art keywords
- concentration
- salt
- mother liquor
- iii
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263306822P | 2022-02-04 | 2022-02-04 | |
| US63/306,822 | 2022-02-04 | ||
| PCT/IB2023/050982 WO2023148680A1 (en) | 2022-02-04 | 2023-02-03 | Methods for large scale synthesis of radionuclide complexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240146015A true KR20240146015A (ko) | 2024-10-07 |
Family
ID=85221934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247028693A Pending KR20240146015A (ko) | 2022-02-04 | 2023-02-03 | 방사성 핵종 복합체의 대규모 합성 방법 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20260053959A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4472678A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025506322A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240146015A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118159303A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3235923A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313964A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202342112A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023148680A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024317528A1 (en) * | 2023-07-31 | 2026-03-05 | Curium Us Llc | [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof |
| WO2025210599A2 (en) | 2024-04-05 | 2025-10-09 | Novartis Ag | Combination therapies with dna damage response inhibitors and [ 177lu]lu-psma-617 |
| WO2026088112A1 (en) | 2024-10-23 | 2026-04-30 | Novartis Ag | Combination therapies with ar-degrading agents and psma-targeting radioligands |
| WO2026099626A1 (en) | 2024-11-08 | 2026-05-15 | Novartis Ag | Methods and systems for manufacturing radiopharmaceuticals |
| WO2026120497A1 (en) | 2024-12-05 | 2026-06-11 | Novartis Ag | Stable radionuclide complex solutions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7358451B2 (ja) * | 2018-07-25 | 2023-10-10 | アドバンスド アクセラレーター アプリケーションズ | 安定な濃厚放射性核種錯体溶液 |
| IL280314B1 (en) * | 2018-07-25 | 2026-07-01 | Advanced Accelerator Applications Sa | Stable and concentrated radionuclide complex solutions |
| WO2020079799A1 (ja) | 2018-10-18 | 2020-04-23 | 三菱電機株式会社 | 付加製造加工機および冷却方法 |
| CN112969675B (zh) * | 2018-10-31 | 2024-12-20 | 意大利国际先进加速器应用有限公司 | 用于合成放射性核素络合物的方法 |
| MX2021015467A (es) * | 2019-06-14 | 2022-01-24 | Edinburgh Molecular Imaging Ltd | Compuestos y metodos de uso. |
-
2023
- 2023-02-03 CA CA3235923A patent/CA3235923A1/en active Pending
- 2023-02-03 EP EP23704451.6A patent/EP4472678A1/en active Pending
- 2023-02-03 KR KR1020247028693A patent/KR20240146015A/ko active Pending
- 2023-02-03 IL IL313964A patent/IL313964A/en unknown
- 2023-02-03 US US18/832,623 patent/US20260053959A1/en active Pending
- 2023-02-03 WO PCT/IB2023/050982 patent/WO2023148680A1/en not_active Ceased
- 2023-02-03 JP JP2024532528A patent/JP2025506322A/ja active Pending
- 2023-02-03 CN CN202380014200.XA patent/CN118159303A/zh active Pending
- 2023-02-04 TW TW112104011A patent/TW202342112A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3235923A1 (en) | 2023-08-10 |
| WO2023148680A1 (en) | 2023-08-10 |
| US20260053959A1 (en) | 2026-02-26 |
| EP4472678A1 (en) | 2024-12-11 |
| CN118159303A (zh) | 2024-06-07 |
| IL313964A (en) | 2024-08-01 |
| TW202342112A (zh) | 2023-11-01 |
| JP2025506322A (ja) | 2025-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260053959A1 (en) | Methods for large scale synthesis of radionuclide complexes | |
| KR102767449B1 (ko) | 방사성핵종 착물의 합성 방법 | |
| AU2007284570B2 (en) | Automated system for formulating radiopharmaceuticals | |
| EP3965751B1 (en) | Para-aminohippuric acid (pah) as a renal protective substance | |
| US20210379212A1 (en) | Stable, concentrated radionuclide complex solutions | |
| WO2020021310A1 (en) | Stable, concentrated radionuclide complex solutions | |
| US20090155167A1 (en) | Automated method | |
| CN116806144A (zh) | 放射性核素络合物的稳定制剂 | |
| JP2025506001A5 (cg-RX-API-DMAC7.html) | ||
| EP3452436B1 (en) | In-kit preparation of gallium-68 labelled radiopharmaceuticals | |
| KR101855509B1 (ko) | 방사성 의약품의 제조를 위한 바이알 키트 및 이를 이용한 방사성 의약품의 제조 방법 | |
| RU2826739C2 (ru) | Способы синтеза радионуклидного комплекса | |
| RU2859685C2 (ru) | Фармацевтическая композиция в форме раствора для внутривенного введения на основе металлокомплексов бета-эмиттеров: лютеций-177 или тербий-161 и агонистов соматостатиновых рецепторов: DOTA-TATE, DOTA-TOC, DOTA-NOC | |
| WO2026099626A1 (en) | Methods and systems for manufacturing radiopharmaceuticals | |
| CN217594625U (zh) | 一种自动化合成氟化铝标记放射性药物的卡套式装置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |